Michael mahler, phd joins exagen as chief scientific officer to enhance leadership in autoimmune diagnostics

Carlsbad, calif., june 23, 2025 (globe newswire) -- exagen inc. (nasdaq: xgn), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of dr. michael mahler as chief scientific officer.
XGN Ratings Summary
XGN Quant Ranking